Thymidine- and AZT-linked 5-(1,3-dioxoalkyl)tetrazoles and 4-(1,3-dioxoalkyl)-1,2,3-triazoles

Tetrahedron Letters

Volumn 53, Issue 5, 2012, Pages 514-518

  Bosch, Lluís ^a   Delelis, Olivier ^b   Subra, Frédéric ^b   Deprez, Eric ^b   Witvrow, Myriam ^c   Vilarrasa, Jaume ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Ecole Normale Superieure de Cachan   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

AZT conjugates; Potential HIV dual inhibitors; Thymidine linked azoles

Indexed keywords

4 ACETYL 1 (4 FLUOROBENZYL) 1,2,3 TRIAZOLE DERIVATIVE; 5 ACETYL 1 (4 FLUOROBENZYL)TETRAZOLE DERIVATIVE; ANTIVIRUS AGENT; COPPER; INTEGRASE; INTEGRASE INHIBITOR; LITHIUM SALT; RALTEGRAVIR; TETRAZOLE DERIVATIVE; THYMIDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL REACTION; CONJUGATION; CONTROLLED STUDY; CYCLOADDITION; DRUG SYNTHESIS; NONHUMAN;

EID: 84355165237     PISSN: 00404039     EISSN: 18733581     Source Type: Journal    
DOI: 10.1016/j.tetlet.2011.11.079     Document Type: Article

References (30)

1. For some very recent, representative reviews, see: L.Q. Al-Mawsawi, and N. Neamati ChemMedChem 6 2011 228 241
2. D.J. McColl, and X. Chen Antiviral Res. 85 2010 101 118
3. M. Jaskolski, J.N. Alexandratos, G. Bujacz, and A. Wlodawer FEBS J. 276 2009 2926 2946
4. D. Hazuda, M. Iwamoto, and L. Wenning Ann. Rev. Pharmacol. Toxicol. 49 2009 377 394
5. A.R.D. Voet, M. De Maeyer, Z. Debyser, and F. Christ Future Med. Chem. 1 2009 1259 1274
6. a values of 2, 4-dioxobutanoic acids (ca. 2.1 and 7.6, in water), and complexation studies, are clearly in favour; see: T.Z. Verbic, B.J. Drakulic, M.F. Zloh, J.R. Pecelj, G.V. Popovic, and I.O. Juranic J. Serb. Chem. Soc. 72 2007 1201 1216
7. M. Sechi, A. Bacchi, M. Carcelli, C. Compari, E. Duce, E. Fisicaro, D. Rogolino, P. Gates, M. Derudas, L.Q. Al-Mawsawi, and N. Neamati J. Med. Chem. 49 2006 4248 4260
8. also see: A. Bacchi, M. Carcelli, C. Compari, E. Fisicaro, N. Pala, G. Rispoli, D. Rogolino, T.W. Sanchez, M. Sechi, and N. Neamati Mol. Pharmaceutics 8 2011 507 519
9. M. Rowley Progr. Med. Chem. 46 2008 1 28 (discovery of raltegravir)
10. C. Hicks, and R.M. Gulick Clin. Infect. Dis. 48 2009 931 939
11. E. Serrao, S. Odde, K. Ramkumar, and N. Neamati Retrovirology 6 2009 25 (pp 1-14) (Raltegravir, Elvitegravir, and "Me-too-gravir")
12. For some very recent reviews, see: J.-L. Blanco, V. Varghese, S.-Y. Rhee, J.M. Gatell, and R.W. Shafer J. Infect. Dis. 203 2011 1204 1214
13. J.D. Croxtall, and L.J. Scott Drugs 70 2010 631 642
14. J.-F. Mouscadet, O. Delelis, A.-G. Marcelin, and L. Tchertanov Drug Resist. Updat. 13 2010 139 150
15. M. Metifiot, C. Marchand, K. Maddali, and Y. Pommier Viruses 2 2010 1347 1366 Also see Ref. 1
16. The working hypothesis of the senior author was and is that even the truncated viral oligodeoxynucleotides incorporating INI-like fragments could render inactive the pre-integration complex and/or may contribute to the blocking of IN in vivo. On the other hand, a simple mixing of L-708,906 (INI) with AZT (NRTI) was proved to be sub-synergistic: W. Pluymers, G. Pais, B. Van Maele, C. Pannecouque, V. Fikkert, T.R. Burke, E. De Clercq, M. Witvrouw, N. Neamati, and Z. Debyser Antimicrob. Agents Chemother. 46 2002 3292 3297 (addition of the INI could be postponed for 7 h after infection)
17. Evaluated with the MTT method [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] in MT-4 cells. Stock solutions of the compounds were prepared in DMSO (10 mg/mL). After 4 days of incubation at 37 °C, the number of viable cells was determined with MTT. Standard parallel tests for cytotoxic effects in uninfected MT-4 cells were always performed. See, e.g.: G. Moncunill, M. Armand-Ugon, I. Clotet-Codina, E. Pauls, E. Ballana, A. Llano, B. Romagnoli, J.W. Vrijbloed, F.O. Gombert, B. Clotet, S. De Marco, and J.A. Este Mol. Pharmacol. 73 2008 1264
18. for entries to N-nitro nucleosides, see: X. Ariza, and J. Vilarrasa J. Org. Chem. 65 2000 2827 2829
19. 2Ar (to be reported elsewhere)
20. Many thymidine analogues are substrates for thymidine kinase 2 (mitochondrial TK2), for the monophosphorylation rate-limiting step. For a review, see: M.-J. Pérez-Pérez, E.-M. Priego, A.-I. Hernández, O. Familiar, M.-J. Camarasa, A. Negri, F. Gago, and J. Balzarini Med. Res. Rev. 28 2008 797 820
21. nonpolar nucleoside mimics are phosphorylated by TK2 (but not by TK1) S.K. Jarchow-Choy, E. Sjuvarsson, H.O. Sintim, S. Eriksson, and E.T. Kool J. Am. Chem. Soc. 131 2009 5488 5494
22. L. Bosch, and J. Vilarrasa Angew. Chem., Int. Ed. 46 2007 3926 3930
23. For very recent reviews on CuAAC, see: S. Díez-González Catal. Sci. Technol. 1 2011 166 178
24. J.E. Hein, and V.V. Fokin Chem. Soc. Rev. 39 2010 1302 1315
25. for a review of CuAAC reactions in the nucleoside field, see: F. Amblard, J.H. Cho, and R.F. Schinazi Chem. Rev. 109 2009 4207 4220
26. For the advantages of acyl cyanides (2-oxonitriles) in the C-acylation of enolates (in general), avoiding the formation of O-acylated by-products, see: C. Wiles, P. Watts, S.J. Haswell, and E. Pombo-Villar Tetrahedron Lett. 43 2002 2945 2948
27. for an alternative procedure, see: Z. Shen, B. Li, L. Wang, and Y. Zhang Tetrahedron Lett. 46 2005 8785 8788
28. T. Janosik, A. Johnson, and J. Bergman Tetrahedron 58 2002 2813 2819 and references cited therein
29. 2, pH 7.0, 37 °C, according to: E. Deprez, S. Barbe, M. Kolaski, H. Leh, F. Zouhiri, C. Auclair, J.C. Brochon, M. Le Bret, and J.F. Mouscadet Mol. Pharmacol. 65 2004 85 98
30. 50 values were determined 48 h post infection as the concentration of drug inhibiting β-galactosidase production by 50% in comparison to results for the untreated infected cells. Cytotoxicities were determined in parallel on uninfected cells